DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT00313183

CompletedPhase 2

A Study to Evaluate Symlin in Adolescent Subjects With Type 1 Diabetes Mellitus

A Randomized, Single-Blind, Dose-Rising, Placebo-Controlled, Crossover Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of SYMLIN in Adolescent Subjects With Type 1 Diabetes Mellitus

Lead sponsor

AstraZeneca

Asset

Pramlintide

Subcutaneous · Amylin analog

Listed sites

3

Recruiting sites

—

Enrollment

12

actual

Study population

Type 1 diabetes

Key I/E criteria

•HbA1c 6-10%•Age 12-17

Primary endpoints

•Pharmacokinetics of Symlin•Safety and tolerability of Symlin

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT00313183
Org study ID137-162

Timeline

Milestones

Study first posted2006-04-12estimated
Last update posted2015-03-06estimated
Study start2006-04 (month precision)
Primary completion2007-08actual (month precision)
Study completion2007-08actual (month precision)

Assets

Investigational agents

Pramlintide

Study populations

Who this study enrolls

Type 1 diabetes

Eligibility

Who can enroll

Minimum age12 Years
Maximum age17 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Diagnosed with type 1 diabetes mellitus for at least 1 year prior to screening
•Be on a stable regimen requiring multiple daily injections of basal and mealtime insulin or continuous subcutaneous insulin infusion for at least 2 weeks prior to screening
•HbA1c between 6.0% and 10.0%, inclusive, at screening
•Body weight >=50 kg at screening

Exclusion criteria

•Currently being treated with the following medications: *Any oral antihyperglycemic agent; *Drugs that directly affect gastrointestinal motility
•Has been previously treated with Symlin/pramlintide (or has participated in a Symlin/pramlintide clinical study)
•Has received any investigational drug within 1 month of screening

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Safety / tolerability / PK
2
Other (unclassified)
1

Safety / tolerability / PK

2 endpoints
Primary/protocol endpoint

To evaluate the pharmacokinetics of Symlin in adolescent subjects with type 1 diabetes

Time frame:single doses

descriptive

Primary/protocol endpoint

To assess the safety and tolerability of Symlin in adolescent subjects with type 1 diabetes

Time frame:single doses

descriptive

Other (unclassified)

1 endpoint
Secondary/protocol endpoint/low confidence

To evaluate the effects of Symlin compared to placebo in adolescent subjects with type 1 diabetes on various pharmacodynamic endpoints

Time frame:single doses

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.